SEC Filings
Qorvo Holders Get 0.960 Skyworks Shares Plus $32.50 Cash As Deal Closes And Nasdaq Listing Ends
Qorvo's board resigned and trading halted before Monday's open as the company became a wholly owned Skyworks subsidiary.
Latest
SEC Filings
RXO Holders Offered $30.25 A Share In C.H. Robinson's $5.8 Billion Cash-And-Stock Deal
C.H. Robinson targets $300 million in cost savings and a 29% premium, with a $175 million breakup fee if RXO walks.
Deals
C.H. Robinson Agrees To Buy RXO For $5.8 Billion, Pausing Buybacks Until Debt Falls
The cash-and-stock deal offers RXO holders $30.25 a share implied, and closing is targeted for the first half of 2027.
SEC Filings
TeraWulf Doubles Muskie Power Contract To 1 Gigawatt And Moves Phase Two Up A Year
An 8-K also says TeraWulf plans to enlarge its secured revolving credit facility and is seeking more senior secured debt.
SEC Filings
Leidos Closes Analogic Venture With 41.5% Stake, Gives Altaris The Board Majority
An 8-K says Leidos keeps minority protections and can seek an exit after the seven-year anniversary of closing.
SEC Filings
FDA Tells Rezolute To Request Pre-BLA Meeting On Ersodetug, But Won't Say If It's Approvable
The agency made its recommendation despite a trial that missed its primary and key secondary endpoints, and it declined to comment on approvability.
Earnings
Strategy Estimates $20.91 Billion Bitcoin Gain For Third Quarter And Releases $4.12 Billion Tax Reserve
An 8-K shows a $4.12 billion tax asset write-down reversed, cutting estimated deferred tax expense to $1.88 billion, in unaudited figures.
Earnings
SS Innovations Targets Europe's CE Mark In Fourth Quarter, FDA Clearance In Early 2027
The surgical robot maker's October deck says its answer to FDA questions is due this month; 87% of 2025 revenue came from India.
SEC Filings
Vaxcyte's 31-Valent Vaccine Hits Every Primary Goal, But Two Serotypes Miss Stricter Bar Against Capvaxive
VAX-31 cleared 17 of 19 shared serotypes against Capvaxive at the tougher threshold; a biologics license filing is planned for the first half of 2028.
SEC Filings
Butterfly Network Adds Chip Executive Mike Noonen As Seventh Director, Effective October 9
Noonen will join the compensation and technology committees and receive a $300,000 restricted stock grant vesting over three years.
SEC Filings
Flex Lines Up $2 Billion Axiom Preferred Deal, With A Redemption Guarantee If Spin-Off Slips Past 2027
General Catalyst and Koch Equity Development would buy the preferred stock, and Flex backs a payout at 115% in cash or 125% in shares.
Deals
DSG's $700 Million Bond Sale Would Fund $35.00 Buyout And Lift Leverage To 4.5 Times
An 8-K and investor slides show the take-private debt would push net leverage above the company's 3.5 to 4.0 times long-term target.